Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Armour stated they would never have any prison plasma.

  • Read more about Armour stated they would never have any prison plasma.

Peter Longstaff was given several vials of Cutter product which was made with the plasma of 297 inmates from Arkansas.

  • Read more about Peter Longstaff was given several vials of Cutter product which was made with the plasma of 297 inmates from Arkansas.

Inmates told Kelly Duda of the extent of subterfuge that was practised in order to enable them to earn a few dollars by selling their plasma.

  • Read more about Inmates told Kelly Duda of the extent of subterfuge that was practised in order to enable them to earn a few dollars by selling their plasma.

Kelly Duda described plasma being sold through brokers, in particular North American Biologics which was bought by Continental Pharma.

  • Read more about Kelly Duda described plasma being sold through brokers, in particular North American Biologics which was bought by Continental Pharma.

Kelly Duda described a connection between Pete Longstaff, a man with haemophilia who received Cutter product that "was made with the plasma of 297 inmates from Arkansas".

  • Read more about Kelly Duda described a connection between Pete Longstaff, a man with haemophilia who received Cutter product that "was made with the plasma of 297 inmates from Arkansas".

A deposition of a prisoner at Louisiana State Penitentiary described a failure to ask about intravenous drug use before donations.

  • Read more about A deposition of a prisoner at Louisiana State Penitentiary described a failure to ask about intravenous drug use before donations.

A prisoner at Wade Prison and Louisiana State Penitentiary donated plasma regularly despite having used intravenous drugs from the age of 13 and having a history of Hepatitis B infection and meningitis.

  • Read more about A prisoner at Wade Prison and Louisiana State Penitentiary donated plasma regularly despite having used intravenous drugs from the age of 13 and having a history of Hepatitis B infection and meningitis.

Evidence from inmates described practices which showed a wholesale disregard for the requirements of the FDA, including no proper physical examinations.

  • Read more about Evidence from inmates described practices which showed a wholesale disregard for the requirements of the FDA, including no proper physical examinations.

A deposition of prisoner at Wade Prison and Louisiana State Penitentiary stated that questionnaires pre-filled by inmates working in the plasmapheresis centres were not checked by the donor.

  • Read more about A deposition of prisoner at Wade Prison and Louisiana State Penitentiary stated that questionnaires pre-filled by inmates working in the plasmapheresis centres were not checked by the donor.

A document confirmed that the use of prison plasma in factor concentrates had been discontinued. The amendment to the internal protocol document recorded that the reason for the change was "a potential safety measure regarding AIDS."

  • Read more about A document confirmed that the use of prison plasma in factor concentrates had been discontinued. The amendment to the internal protocol document recorded that the reason for the change was "a potential safety measure regarding AIDS."

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 306
  • Page 307
  • Page 308
  • Page 309
  • Current page 310
  • Page 311
  • Page 312
  • Page 313
  • Page 314
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.